title: [Focus on tumor immunology of transitional cell carcinoma].
authors.affiliation: Klinik fũr Urologie und Kinderurologie, Philipps-Universität Marburg, Marburg.olbert@med.uni-marburg.de
authors.forename: P J
authors.initials: PJ
authors.lastname: Olbert
authors.forename: A J
authors.initials: AJ
authors.lastname: Schrader
authors.forename: A
authors.initials: A
authors.lastname: Hegele
authors.forename: R
authors.initials: R
authors.lastname: Hofmann
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000283:Administration, Intravesical; D000818:Animals; D001500:BCG Vaccine / Q000008:administration & dosage / Q000276:immunology; D002295:Carcinoma, Transitional Cell / Q000276:immunology* / Q000473:pathology / Q000628:therapy; D003131:Combined Modality Therapy; D004195:Disease Models, Animal; D004598:Electrosurgery; D006801:Humans; D051379:Mice; D009367:Neoplasm Staging; D009838:Oligodeoxyribonucleotides / Q000008:administration & dosage / Q000276:immunology; D051217:Toll-Like Receptor 9 / Q000502:physiology; D001749:Urinary Bladder Neoplasms / Q000276:immunology* / Q000473:pathology / Q000628:therapy
chemical_list: D000276:Adjuvants, Immunologic; D001500:BCG Vaccine; C408982:CPG-oligonucleotide; D009838:Oligodeoxyribonucleotides; D051217:Toll-Like Receptor 9